Development of micro <scp>RNA</scp> therapeutics is coming of age
-
- Eva van Rooij
- Hubrecht Institute KNAW and University Medical Center Utrecht The Netherlands
-
- Sakari Kauppinen
- Department of Clinical Medicine Aalborg University Aalborg Denmark
書誌事項
- 公開日
- 2014-06-16
- 権利情報
-
- http://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.15252/emmm.201100899
- 公開者
- Springer Science and Business Media LLC
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p> Micro <jats:styled-content style="fixed-case">RNA</jats:styled-content> s (mi <jats:styled-content style="fixed-case">RNA</jats:styled-content> s) play key regulatory roles in diverse biological processes and are frequently dysregulated in human diseases. Thus, mi <jats:styled-content style="fixed-case">RNA</jats:styled-content> s have emerged as a class of promising targets for therapeutic intervention. Here, we describe the current strategies for therapeutic modulation of mi <jats:styled-content style="fixed-case">RNA</jats:styled-content> s and provide an update on the development of mi <jats:styled-content style="fixed-case">RNA</jats:styled-content> ‐based therapeutics for the treatment of cancer, cardiovascular disease and hepatitis C virus ( <jats:styled-content style="fixed-case">HCV</jats:styled-content> ) infection. </jats:p>
収録刊行物
-
- EMBO Molecular Medicine
-
EMBO Molecular Medicine 6 (7), 851-864, 2014-06-16
Springer Science and Business Media LLC
